G-PUR® for Reduced Lead Bioavailability

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Lead Exposure
Interventions
DEVICE

G-PUR® 2x 2.0 g oral suspension

Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake

DEVICE

G-PUR® 1x 2.0 g oral suspension

Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake

DEVICE

Placebo oral suspension

Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake

Trial Locations (1)

Unknown

Department of Clinical Pharmacology, Medical University of Vienna, Vienna

All Listed Sponsors
lead

Glock Health, Science and Research GmbH

INDUSTRY

NCT04138693 - G-PUR® for Reduced Lead Bioavailability | Biotech Hunter | Biotech Hunter